Related Experiment Video
Updated: Jun 5, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate Cancer: Staging, Progression, and Treatment
Nicole LaBrecque1, Alexia Romano2, Jared LeBlanc3
1Dana-Farber Cancer Institute, Boston, Massachusetts.
Journal of Nuclear Medicine Technology
|June 3, 2026
Summary
Prostate cancer is increasingly diagnosed in younger men, possibly due to increased prostate-specific antigen (PSA) screening. Diagnosis and treatment depend on staging, utilizing tools like PSA levels, imaging, and Gleason scores.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer traditionally affects older men, but recent data indicate a trend towards earlier diagnoses.
- Increased prostate-specific antigen (PSA) screening may contribute to the rising incidence in younger populations.
Purpose of the Study:
- To summarize the current understanding of prostate cancer diagnosis and staging, particularly in the context of shifting age demographics.
- To highlight the role of PSA screening and various diagnostic tools in prostate cancer evaluation.
Main Methods:
- Review of emerging evidence on prostate cancer incidence trends.
- Analysis of the diagnostic significance of prostate-specific antigen (PSA) levels.
- Overview of imaging and assessment tools used for staging prostate cancer.
Main Results:
- Evidence suggests a shift in prostate cancer diagnosis towards younger age groups.
- Elevated PSA levels correlate with an increased likelihood of prostate cancer.
- Staging involves multiple modalities including CT, MRI, bone scans, PSMA PET/CT, and Gleason score.
Conclusions:
- Prostate cancer management is individualized, based on stage, risk, and patient factors.
- Accurate staging is crucial for effective prostate cancer diagnosis and treatment planning.
- A combination of screening, imaging, and pathological assessment is essential for comprehensive prostate cancer care.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...